News

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

Catch up on this week's highlights in retina.

The trial will be evaluating AXPAXLI dosed every 6 months vs aflibercept (2 mg) dosed every 8 weeks in treatment-naive patients with wet AMD.

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

This acquisition will include Adverum’s lead candidate, Ixo-vec, a gene therapy treatment for wet AMD.

Emerging anti-VEGF agents offer enhanced durability and anatomic outcomes in retinal disease.

A study reveals that lesion characteristics in geographic atrophy significantly influence growth rates, highlighting the need for targeted treatment strategies.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr Feistmann in an overview of office-based surgery, with actionable advice for retina specialists considering this approach.

Topcon Healthcare enhances its AI capabilities by acquiring Toku, Inc, aiming to revolutionize eye care with advanced predictive health insights.

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

New research highlights iron dysregulation's role in dry AMD, suggesting transferrin as a promising treatment to slow disease progression.

Retina specialists share their perspectives on evolving anti-VEGF therapy, pipeline treatments, and strategies to enhance patient outcomes.

Xelafaslatide (formerly ONL1204) is a small-molecule Fas inhibitor designed to protect key retinal cells from cell death that occurs across multiple retinal diseases and conditions such as geographic atrophy.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

Innovative retinal therapies are advancing through FDA trials, promising breakthroughs in treating various retinal diseases.

Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.

Catch up on this week's highlights in retina.

A recent study reveals that systemic chemotherapy significantly reduces mortality and enucleation rates in retinoblastoma, enhancing patient outcomes.

While the STAR trial showed significant reductions in myopia progression, including over 50% in fast-progressing children, the FDA requires additional evidence to support US approval.

Gildeuretinol has also been evaluated in atrophic age-related macular degeneration, said Philip J. Ferrone, MD

The newest research findings create "tangible benchmarks" for how earlier treatment can lead to better outcomes, said Dr. Kim.

During the American Academy of Ophthalmology annual scientific meeting, the organization shared breaking news and updates from ongoing projects.

The CNPV program was announced by the FDA in June 2025 and offers companies the opportunity to reduce standard application review times from 10–12 months to just 1–2 months.

The topical therapy offers a less invasive approach to corneal cross-linking, with commercial availability anticipated in early 2026.

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration.

DURAVYU is being developed as a potential sustained-delivery treatment for patients suffering from serious retinal diseases.